文献速递临床试验与 GCP

儿童PICU静脉输液:生理盐水与平衡液随机对照试验方案

0.9% Sodium chloride solution versus Plasma-Lyte 148 versus compound sodium lacTate solution in children admitted to PICU-a randomized controlled trial (SPLYT-P): study protocol for an intravenous fluid therapy trial.
PubMed 文献 · Trials · 2021-07-03

本研究为单中心、开放标签、平行1:1:1随机对照试验,纳入<16岁入住PICU并接受静脉输液治疗的儿童,比较0.9%氯化钠、Plasma-Lyte 148与复方乳酸钠对血清氯升高的影响。主要结局为随机后48小时内血清氯升高≥5mmol/L,计划入组480例,主要分析采用意向性治疗原则。

要点

  • 在危重儿童中比较生理盐水与两种平衡液对高氯血症风险的影响。
  • 主要结局是随机后48小时内血清氯升高≥5mmol/L。
  • 计划入组480例,按1:1:1随机分配,采用意向性治疗分析。

核心结论

  • 该方案旨在验证平衡液能否降低危重儿童血清氯升高的发生率。

研究设计与样本

  • 单中心、开放标签、平行1:1:1随机对照试验,计划纳入480例<16岁PICU患儿。

关键数值与推荐

  • 主要结局为随机后48小时内血清氯升高≥5mmol/L。
  • 纳入标准:<16岁入住ICU且入院后4小时内接受静脉输液治疗。
  • 干预包括维持输液和推注输液。

临床怎么用

  • 为PICU儿童静脉输液选择提供比较生理盐水与平衡液对高氯血症风险的证据。

局限性

  • 单中心、开放标签设计,干预实施层面未设盲。
  • 排除心脏疾病或创伤性脑损伤后入院的PICU患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intravenous fluid therapy represents the most common intervention critically ill patients are exposed to. Hyperchloremia and metabolic acidosis associated with 0.9% sodium chloride have been observed to lead to worse outcomes, including mortality. Balanced solutions, such as Plasma-Lyte 148 and Compound Sodium Lactate, represent potential alternatives but the evidence on optimal fluid choices in critically ill children remains scarce. This study aims to demonstrate whether balanced solutions, when used as intravenous fluid therapy, are able to reduce the incidence of a rise in serum chloride level compared to 0.9% sodium chloride in critically ill children. METHODS: This is a single-centre, open-label randomized controlled trial with parallel 1:1:1 assignment into three groups: 0.9% sodium chloride, Plasma-Lyte 148, and Compound Sodium Lactate solutions for intravenous fluid therapy. The intervention includes both maintenance and bolus fluid therapy. Children aged < 16 years admitted to intensive care and receiving intravenous fluid therapy during the first 4 h of admission are eligible. The primary outcome measure is a ≥ 5mmol/L increase in serum chloride level within 48 h post-randomization. The enrolment target is 480 patients. The main analyses will be intention-to-treat. DISCUSSION: This study tests three types of intravenous fluid therapy in order to compare the risk of hyperchloremia associated with normal saline versus balanced solutions. This pragmatic study is thereby assessing the most common intervention in paediatric critical care. This is a single-centre open-label study with no blinding at the level of delivery of the intervention. Certain paediatric intensive care unit (PICU) patient groups such as those admitted with a cardiac condition or following a traumatic brain injury are excluded from this study. TRIAL REGISTRATION: The study has received ethical approval (HREC/19/QCHQ/53177: 06/06/2019). It is registered in the Australian New Zealand Clinical Trials Registry ( ACTRN12619001244190 ) from 9th September 2019. Recruitment commenced on 12th November 2019. The primary results manuscript will be published in a peer-reviewed journal.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Raman S, Schibler A, Marsney RL, et al. 0.9% Sodium chloride solution versus Plasma-Lyte 148 versus compound sodium lacTate solution in children admitted to PICU-a randomized controlled trial (SPLYT-P): study protocol for an intravenous fluid therapy trial. Trials. 2021. PMID: 34217337. doi:10.1186/s13063-021-05376-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。